학술논문
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
Document Type
Article
Author
Source
In European Journal of Cancer September 2021 154:288-295
Subject
Language
ISSN
0959-8049